Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Other Non-Current Assets (2016 - 2026)

Champions Oncology has reported Other Non-Current Assets over the past 16 years, most recently at $196000.0 for Q1 2026.

  • For Q1 2026, Other Non-Current Assets rose 5.95% year-over-year to $196000.0; the TTM value through Jan 2026 reached $196000.0, up 5.95%, while the annual FY2025 figure was $196000.0, 5.95% up from the prior year.
  • Other Non-Current Assets for Q1 2026 was $196000.0 at Champions Oncology, roughly flat from $196000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $196000.0 in Q2 2025 and troughed at $15000.0 in Q1 2022.
  • A 5-year average of $127529.4 and a median of $185000.0 in 2023 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: crashed 82.56% in 2022 and later skyrocketed 1133.33% in 2023.
  • Year by year, Other Non-Current Assets stood at $15000.0 in 2022, then skyrocketed by 1133.33% to $185000.0 in 2023, then changed by 0.0% to $185000.0 in 2024, then increased by 5.95% to $196000.0 in 2025, then changed by 0.0% to $196000.0 in 2026.
  • Business Quant data shows Other Non-Current Assets for CSBR at $196000.0 in Q1 2026, $196000.0 in Q4 2025, and $196000.0 in Q3 2025.